Roche Holding AG (RHHBY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Roche Holding Ltd.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:01.894 You are 00:00:01.894 -- 00:00:06.222 invited to send in questions for this throughout the entire session using the Q&A functionality 00:00:06.222 -- 00:00:10.770 of Zoom. In addition to that, you may also raise your virtual hand to address your questions 00:00:10.770 -- 00:00:15.058 verbally. For participants joining via phone, to raise your hand, use star 9 on your 00:00:15.058 -- 00:00:19.085 phone's dial pad. When you then get selected to ask your questions, please follow the 00:00:19.085 -- 00:00:22.458 instructions from the phone and press star 6 to unmute yourself. 00:00:22.458 -- 00:00:27.143 One last remark, if you'd like to follow the presented slides on your end as well, please 00:00:27.143 -- 00:00:31.748 feel free to go to www.wolf.com slash investors to download the presentation. 00:00:31.748 -- 00:00:36.133 At this time, it's my pleasure to introduce you to Thomas Schieneker, CEO of Wolf Group. 00:00:36.133 -- 00:00:39.396 Mr. Schieneker, the stage is yours. 00:00:39.396 -- 00:00:44.342 Thank you very much, and good morning, good afternoon, or good evening, wherever you 00:00:44.342 -- 00:00:49.367 are. I'm really happy to talk to you about our half-year results, which have 00:00:49.367 -- 00:00:52.469 been extremely strong. 00:00:54.385 -- 00:00:59.014 So let me kick it off on this slide. So overall, our group sales increased by 7%. 00:00:59.014 -- 00:01:00.517 So 00:01:00.517 -- 00:01:05.808 very strong growth by pharma with 10%. In fact, if you look at the momentum 00:01:05.808 -- 00:01:11.029 in Q2, pharma even grew by 11%. Diagnostics was flat, so 00:01:11.029 -- 00:01:16.061 very similar to what we saw in the first quarter, and this is purely due 00:01:16.061 -- 00:01:21.113 to the China healthcare pricing refor...